Phase III trial in 650 patients with low-risk DLBCL: PET-adapted R-CHOP (4 cycles if PET-negative after 2) was non-inferior to 6 cycles for 3-year PFS (92.0% vs 89.2%), with fewer grade ≥3 adverse events (54.7% vs 62.7%).
RCTn = 650
Michot et al. Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial